CD274 and breast cancer: In the recently published version (NCCN Version 3.2020 and 5th ESO-ESMO) of these guidelines [20,21], immunotherapy drugs are included as first-line therapy for programmed death ligand-1 (PD-L1)-positive metastatic BC.